iFyber
iFyber is a U.S.-based preclinical contract research organization (CRO) providing custom laboratory testing and regulatory consulting—including biofilm, antimicrobial, tissue model, LC-MS, and virology services—to medical device, wound care, diagnostic, and specialty textile developers.
- Company typePrivate
- Founded2009
- HeadquartersIthaca, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What iFyber does
iFyber, LLC is a preclinical contract research organization (CRO) founded in 2009 and based in Ithaca, New York, providing fee-for-service laboratory testing and regulatory consulting to companies developing medical devices, wound care products, diagnostics, and specialty textiles. The company's service catalog is organized around four technical pillars: microbial control (biofilm testing, antimicrobial efficacy testing, and sterilization validation); cell and tissue culture (cell-based assays, ex vivo porcine dermal models, 3D Human Epidermis Equivalent tissue models, and histology/imaging); LC-MS analytical services for proteomics, biomarker, and small-molecule analysis; and virology plus analytical chemistry including monoclonal antibody characterization and chemical detection diagnostics. Notable proprietary methodology includes the ex vivo porcine dermal biofilm model—documented in multiple white papers—that bridges in vitro screening and in vivo animal studies for antimicrobial and anti-biofilm work, and the 3D HEE tissue model for wound care and biomaterials testing.
iFyber operates as a B2B enterprise services business, engaging clients through direct sales, website contact, and email to scope custom project work; pricing is not publicly disclosed and contracts are quoted on a per-project basis. Primary customer segments are medical device and wound care developers—often requiring FDA 510(k) submission support, biocompatibility evaluation, and antimicrobial or biofilm efficacy testing—supplemented by diagnostics companies and specialty textile manufacturers. The company has produced at least one disclosed co-development engagement, a 2021 collaboration with SweetBio, Inc. evaluating the APIS wound product via a joint publication in the International Journal of Biomaterials. No institutional venture capital is disclosed; the only recorded funding event is a $150,000 National Science Foundation grant in December 2012, suggesting the company has been bootstrapped or founder-financed for most of its operating life. Leadership team, headcount exact figure, and revenue figures are not disclosed in the public source set, indicating a small, privately held operation (headcount stated as 11–50 employees) operating primarily in North America.
iFyber firmographics
Firmographics- Name
- iFyber
- Legal name
- iFyber, LLC
- Website
- https://ifyber.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- iFyber is a U.S.-based preclinical contract research organization (CRO) providing custom laboratory testing and regulatory consulting—including biofilm, antimicrobial, tissue model, LC-MS, and virology services—to medical device, wound care, diagnostic, and specialty textile developers.
- Ownership category
- akta.pro rank
iFyber industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Testing Laboratories and Services (541380), Other Scientific and Technical Consulting Services (541690), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industries
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Regulatory Consulting & Compliance Program Management (FDA/USDA/EFSA) (AFALADAC)
Keywords
Where iFyber is headquartered
LocationHeadquarters
- HQ city
- Ithaca
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
iFyber business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services: Fee-for-service preclinical research contracts providing laboratory testing, method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
iFyber product offering
Product offeringCore offering
iFyber is a preclinical contract research organization (CRO) that provides fee-for-service laboratory testing, custom method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies. Its services span microbial control (biofilm testing, antimicrobial efficacy, sterilization validation), cell and tissue culture (cell-based assays, ex vivo and 3D tissue models, histology and imaging), LC-MS analytical chemistry, virology testing, monoclonal antibody characterization, and chemical detection diagnostics.
Product overview
iFyber is a preclinical contract research organization (CRO) providing integrated research services for medical device, wound care, diagnostic, and specialty textile development. The company operates as a unified service platform rather than a software product, offering consulting-driven experimental design combined with laboratory execution across multiple testing disciplines. The portfolio encompasses microbial control services (biofilm testing, antimicrobial efficacy testing, sterilization validation), cell and tissue culture capabilities (cell-based assays, tissue models including ex vivo porcine dermal models and 3D Human Epidermis Equivalent, histology and imaging), LC-MS analytical services, virology testing, analytical services for monoclonal antibodies and chemical detection, and specialized expertise in medical devices, wound care devices, diagnostics, and specialty textiles. White papers documenting proprietary methodologies include ex vivo biofilm models, biofilm visualization techniques, 3D HEE models, dental device biocompatibility frameworks, antibiotic and antifungal efficacy screening, and tissue decellularization evaluation.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical CRO Services Integrated preclinical contract research services encompassing study design, experimental execution, and regulatory consulting to support medical device, wound care, diagnostic, and specialty textile product development.
- Microbial Control Services
Companies that use iFyber
Customer profileSegments4 records
Ideal customer profiles4 records
iFyber technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
iFyber partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SweetBio, Inc.minorCollaborative research partnership for wound care product evaluation. Joint publication titled 'Microenvironment Influence of a Novel Bioengineered Wound Product, APIS®: A Preliminary In Vitro Analysis of Inflammatory Marker and Growth Factor Secretion' published in International Journal of Biomaterials (2021). The partnership evaluated the novel APIS wound product's ability to balance wound microenvironment by reducing MMP-9/TIMP-1 ratio and triggering growth factor release from fibroblasts.
Recent moves5 records
Expansion highlights4 records
iFyber competitors and assessment
Company assessmentDirect peers
- Nelson Laboratories: Nelson Labs is a dedicated microbiology and analytical testing CRO specializing in medical device sterilization validation, biocompatibility, and antimicrobial efficacy testing. It is a direct peer to iFyber given the highly overlapping focus on medical device and wound care product safety, efficacy, and FDA submission-support testing.
- Toxikon Corporation: Toxikon is a preclinical CRO focused on medical device biocompatibility, toxicology, and materials characterization. It directly competes with iFyber's medical device safety and biocompatibility testing work for FDA submissions.
- Microtest Laboratories: Microtest Laboratories is a contract testing lab focused on medical device microbiology, sterilization validation, and packaging/testing services. It is a direct peer to iFyber given the overlapping focus on medical device antimicrobial efficacy and sterilization validation workflows.
- North American Science Associates (NAMSA): NAMSA is a medical device-focused CRO offering preclinical, biological safety, and regulatory consulting services. It directly competes with iFyber's integrated preclinical testing plus FDA 510(k) regulatory support for medical device developers.
Broad incumbents
- Labcorp Drug Development (formerly Covance): Labcorp's development services business spans central lab, preclinical, and analytical services across pharma and medtech. It is a broad incumbent whose central lab and preclinical offerings overlap with iFyber's analytical and preclinical testing capabilities.
- Eurofins Scientific: Eurofins is a global analytical testing incumbent with dedicated medical device, pharmaceutical, and microbiology service lines. It is comparable as a broad incumbent offering overlapping antimicrobial, biocompatibility, and analytical services—though at much greater scale and geographic breadth than iFyber.
- WuXi AppTec: WuXi AppTec is a large global CRO/CDMO with preclinical testing, analytical chemistry, and regulatory capabilities. It is comparable as a broad incumbent offering testing services that overlap with iFyber's preclinical and analytical offerings, primarily serving medical device and biopharma clients.
- Charles River Laboratories: Charles River is a global life sciences CRO incumbent with significant preclinical safety, microbiology, and endotoxin testing capabilities. It is comparable as a broad incumbent serving medical device and biopharma end-markets that also overlap with iFyber's preclinical testing focus.
- BioReliance (Merck KGaA / Sigma-Aldrich): BioReliance is a biopharmaceutical testing services provider offering biosafety, analytical, and microbiology testing to medical product developers. It is comparable as a broad incumbent whose microbiology and analytical offerings overlap with iFyber's antimicrobial and LC-MS work.
Emerging players
- Pace Analytical Life Sciences: Pace Analytical provides analytical and life sciences testing services including microbiology and chemistry for regulated industries. It is an emerging/larger-but-focused player whose analytical chemistry and microbiology capabilities partially overlap with iFyber's LC-MS and microbial control services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
iFyber social profiles
Digital presenceiFyber financial estimates
Financial estimateRevenue estimate
Valuation estimate
iFyber leadership team
Management profileNumber of profiles
iFyber funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iFyber M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iFyber
What does iFyber do?
iFyber is a preclinical contract research organization (CRO) that provides fee-for-service laboratory testing, custom method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies. Its services span microbial control (biofilm testing, antimicrobial efficacy, sterilization validation), cell and tissue culture (cell-based assays, ex vivo and 3D tissue models, histology and imaging), LC-MS analytical chemistry, virology testing, monoclonal antibody characterization, and chemical detection diagnostics.
Is iFyber a public or private company?
iFyber is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was iFyber founded?
iFyber was founded in 2009. It employs 11 to 50 people.
Where is iFyber based?
iFyber is headquartered in Ithaca, United States, in the North America region.
How does iFyber make money?
One revenue line is on record: contract Research Services.
Who are iFyber's main competitors?
Direct peers on record are Nelson Laboratories, Toxikon Corporation, Microtest Laboratories and North American Science Associates (NAMSA). Broad incumbents are Labcorp Drug Development (formerly Covance), Eurofins Scientific, WuXi AppTec, Charles River Laboratories and BioReliance (Merck KGaA / Sigma-Aldrich). Pace Analytical Life Sciences is listed as an emerging player.
Does iFyber have an API?
No public API is recorded for iFyber.
What industry is iFyber in?
iFyber's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 541380 and its SIC code is 8731.